Proctitis ulcerosa activa y refractaria: Una puesta al día: [revisión] / Active and refractory ulcerative proctitis: An update: [review]
Rev. méd. Chile
;
138(1): 109-116, ene. 2010. ilus
Article
Dans Espagnol
| LILACS
| ID: lil-542056
ABSTRACT
Ulcerative colitis (UC) is a chronic inflammatory disease of unknown etiology that affects a variable length of the colon, starting from the rectum. When the disease is confined to the rectum is called ulcerative proctitis (UP). Several studies have unsuccessfully attempted to determine the factors that determine the extent of involvement. The goals of therapy in UP are to induce and maintain remission of symptoms and disease. Topical treatment with 5-aminosalicylates (5-ASA) is the treatment of choice to induce remission. In the maintenance phase, long-term follow up studies suggest that treatment with 5-ASA is better than placebo, to maintain the disease inactive. For those patients that do not respond to treatment with topical 5-ASA or have a moderate to severe disease, there are additional therapies such as oral 5-ASA, topical or systemic corticosteroids, immunomodulators, biological therapies (Infliximab) and cyclosporine. Surgery is seldom needed.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Rectite
/
Rectocolite hémorragique
/
Anti-inflammatoires
Type d'étude:
Essai clinique contrôlé
/
Étude observationnelle
/
Étude pronostique
Limites du sujet:
Humains
langue:
Espagnol
Texte intégral:
Rev. méd. Chile
Thème du journal:
Médicament
Année:
2010
Type:
Article
Pays d'affiliation:
Chili
Institution/Pays d'affiliation:
Pontificia Universidad Católica de Chile/CL
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS